Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 1/20 | 0.42 |
| ▸ | SREBF2 | Q12772 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
| ▸ | MAPKAPK2 | P49137 | 5/20 | 0.38 |
| ▸ | PPARA | Q07869 | 4/20 | 0.38 |
| ▸ | F10 | P00742 | 2/20 | 0.38 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.36 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22009250 | 0.92 | CYP17A1 (0.46) | CYP17A1SREBF2DRD2MAPK14MAPKAPK2 | |
| SCHEMBL22009252 | 0.91 | CYP17A1 (0.41) | CYP17A1SREBF2DRD2MAPK14MAPKAPK2 | |
| SCHEMBL24454240 | 0.83 | CYP17A1 (0.38) | CYP17A1SREBF2DRD2MAPK14MAPKAPK2 | |
| SCHEMBL22008651 | 0.81 | CYP17A1 (0.46) | CYP17A1DRD2MAPK14PPARAF10 | |
| SCHEMBL24206947 | 0.81 | SIRT2 (0.33) | CYP17A1SREBF2DRD2MAPK14MAPKAPK2 | |
| SCHEMBL22008652 | 0.81 | CYP17A1 (0.42) | CYP17A1DRD2MAPK14PPARAF10 | |
| SCHEMBL22009247 | 0.80 | CD274 (0.40) | DRD2F10 | |
| SCHEMBL17512692 | 0.80 | ATR (0.41) | CYP17A1SREBF2MAPK14MAPKAPK2HDAC1 | |
| SCHEMBL30688723 | 0.79 | CA12 (0.47) | — | |
| SCHEMBL16232858 | 0.78 | PTPN11 (0.44) | CYP17A1SREBF2MAPK14MAPKAPK2HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220185803-A1 | MACROCYCLIC COMPLEXES OF ALPHA-EMITTING RADIONUCLIDES AND THEIR USE IN TARGETED RADIOTHERAPY OF CANCER | CORNELL UNIVERSITY (US) | 2022-06-16 | — | — | US | disclosed |
| US-20220177461-A1 | MACROCYCLIC COMPLEXES OF ALPHA-EMITTING RADIONUCLIDES AND THEIR USE IN TARGETED RADIOTHERAPY OF CANCER | CORNELL UNIVERSITY (US) | 2022-06-09 | — | — | US | disclosed |
| US-20220016277-A1 | MACROCYCLIC COMPLEXES OF RADIONUCLIDES AND THEIR USE IN RADIOTHERAPY OF CANCER | CORNELL UNIVERSITY (US) | 2022-01-20 | — | — | US | disclosed |
| US-20200157087-A1 | MACROCYCLIC COMPLEXES OF ALPHA-EMITTING RADIONUCLIDES AND THEIR USE IN TARGETED RADIOTHERAPY OF CANCER | CORNELL UNIVERSITY (US) | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220185803-A1 | MACROCYCLIC COMPLEXES OF ALPHA-EMITTING RADIONUCLIDES AND THEIR USE IN TARGETED RADIOTHERAPY OF CANCER | PSMA1, FOLH1, KLK3 | CYP17A1 1161/4885SREBF2 3133/4885DRD2 3095/4885 |
| US-20200157087-A1 | MACROCYCLIC COMPLEXES OF ALPHA-EMITTING RADIONUCLIDES AND THEIR USE IN TARGETED RADIOTHERAPY OF CANCER | PSMA1, FOLH1, KLK3 | CYP17A1 1161/4885SREBF2 3133/4885DRD2 3095/4885 |
| US-20220016277-A1 | MACROCYCLIC COMPLEXES OF RADIONUCLIDES AND THEIR USE IN RADIOTHERAPY OF CANCER | PSMA1, KLK3, FOLH1 | CYP17A1 494/4885SREBF2 2714/4885DRD2 3499/4885 |
| US-20220177461-A1 | MACROCYCLIC COMPLEXES OF ALPHA-EMITTING RADIONUCLIDES AND THEIR USE IN TARGETED RADIOTHERAPY OF CANCER | PSMA1, FOLH1, KLK3 | CYP17A1 1161/4885SREBF2 3133/4885DRD2 3095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.